Other languages TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
15.85 ^USD	+0.25%		-2.76%	-7.20%

May. 01	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT
May. 01	Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	May. 01
TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	Apr. 18
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	Apr. 18
Tg Therapeutics Insider Sold Shares Worth $351,340, According to a Recent SEC Filing	Mar. 13
TG Therapeutics Says Updated Data in Briumvi Study Shows Manageable Safety, Tolerability Profile	Mar. 01
Sector Update: Health Care Stocks Softer Wednesday Afternoon	Feb. 28
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surge	Feb. 28
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surging in Pre-Trade	Feb. 28
TG Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
TG Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28
TG Therapeutics to Receive $12.5 Million Milestone Payment for Launch of Briumvi in Europe	Feb. 26
Sector Update: Health Care Stocks Higher in Afternoon Trading	Jan. 10
TG Therapeutics Shares Fall After Reporting Net Product Preliminary Revenues for Briumvi; Provides 2024 Targets	Jan. 10
TG Therapeutics Reports Net Product Preliminary Q4 and 2023 US Revenue for Briumvi; Provides 2024 Targets	Jan. 10
Looming Big Bank Earnings, Inflation Data Fuel Cautiousness, Driving Muted Premarket Action for US Equity Futures	Jan. 10
TG Therapeutics Acquires Worldwide License to Precision BioSciences' Allogeneic CD19 CAR T Cell Therapy Program	Jan. 09
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases	Jan. 09
Tg Therapeutics Insider Sold Shares Worth $333,025, According to a Recent SEC Filing	Jan. 09
TG Therapeutics Insider Sold Shares Worth $809,431, According to a Recent SEC Filing	Jan. 05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Other languages

Filters